- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04019522
American Heart Association- Stroke/Hypoxia Study
An Exploration of Acute Intermittent Hypoxia as a Tool to Enhance Neural Recovery in Stroke Survivors; a Pilot Safety Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stroke is the second leading cause of death and a leading cause of long-term disability worldwide. Despite the spontaneous recovery that occurs following a hemispheric stroke, more than half of stroke patients show substantial residual impairments, imposing a significant human and economic burden. This burden is likely to increase in coming decades, due to a rapidly aging population, and the associated progression of cardiovascular risk factors. Accordingly, new interventions to alleviate impairment in stroke survivors are urgently needed. The development and testing of one such novel intervention, termed Acute Intermittent Hypoxia (AIH), is the primary focus of this AHA Innovative Project Award.
The aim is to answer questions related to safety and preliminary efficacy of AIH in stroke survivors. First, the Investigators will establish whether brief reductions in inhaled oxygen concentration can be safely tolerated in stroke survivors. A clinician will closely monitor subjects for any adverse events.
The second aim is to establish the effects of AIH on elbow flexion/extension strength, and on hand grip and pinch strength. Subjects will be monitored closely for any adverse events during these experiments. Data will be analyzed to determine if there is an improvement in key outcomes at any dose level.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Shirley Ryan AbilityLab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
Age ≥18 years;
A first time, unilateral, ischemic, hemispheric stroke, confirmed by magnetic resonance imaging (MRI);
Chedoke assessment > 3
Ability to open and close affected hand
Able to understand and communicate in English
Be able to consent independently
≥ 6 months post stroke
Must have a hemoglobin level above 10g/dl (to be confirmed using handheld noninvasive lab equipment)
Must have ability to attend research visits with a companion for assistance
WOCBP must be comfortable confirming negative pregnancy prior to hypoxia experimental therapy.
Exclusion criteria:
Brain stem or cerebellar stroke; mean Fazekas score rated on initial fluid-attenuated inversion recovery MRI ≥3
Severe aphasia, preventing subject from understanding the protocol and giving written consent;
History of prior neurological disorder;
Pre-existing hypoxic pulmonary disease,
Severe hypertension (>160/100)
Ischemic cardiac disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypoxia
During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position.
AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position.
Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
|
An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject.
Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2.
The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical/neurological status over the duration of the study
Time Frame: 6 days
|
All adverse events will be reviewed for safety and study continuation by the medical monitor.
|
6 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
National Institute of Health Stroke Scale (NIHSS)
Time Frame: 6 days
|
is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke.
The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.
The individual scores from each item are summed in order to calculate a patient's total NIHSS score ranging from 0-42.
|
6 days
|
Fugl- Meyer Assessment
Time Frame: 6 days
|
Each test element will be graded on a 3-point ordinal scale and summed up to provide a maximum upper limb score of 66. Reliability and validity have been demonstrated.
The FMA will be administered while the subject is seated.
|
6 days
|
Modified Ashworth Scale
Time Frame: 6 days
|
This scale allows for characterization of increases in muscle tone, from low or normal tone to complete limb rigidity.
Specifically, we will evaluate the elbow flexors, bilaterally
|
6 days
|
Grip strength
Time Frame: 6 days
|
A dynamometer measures maximum gross grasp (lb.) averaged over three attempts with each hand.
The minimum possible value of zero lb. will be assigned when the participant cannot actively flex the fingers or grasp the dynamometer.
Completed bilaterally, if possible
|
6 days
|
Pinch Strength
Time Frame: 6 days
|
Hydraulic Handheld Dynamometer): A dynamometer measures maximum gross grasp (lb.) averaged over 3 attempts with each hand.
The minimum possible value of zero lb. will be assigned when the participant cannot actively flex the fingers or grasp the dynamometer.
|
6 days
|
Elbow strength
Time Frame: 6 days
|
monitoring changes in isometric elbow flexion force using a dynamometer.
A total of three trials will be taken on each side, with a rest break between trials.
The average of the three trials will be recorded.
|
6 days
|
D-KEFS Color-Word Interference Test
Time Frame: 6 days
|
A neuropsychological measure that seeks to evaluate attention and inhibition.
Subjects will be asked to read words or name ink colors as quickly as possible within a given time limit.
The test supplies the examiner with three separate scores, including an ability to calculate an interference score.
This final score allows for interpretation of cognitive flexibility, creativity and cognitive stress.
This measure will be utilized to monitor subjects throughout their participation at specific time-points.
Audio recording may be taken to ensure accurate recording of responses
|
6 days
|
5 minute neurological test
Time Frame: 6 days
|
Quick short tests to assess clinical status
|
6 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zev Rymer, MD/PhD, Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU: 00208610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Acute Intermittent Hypoxia (AIH)
-
University of FloridaCompletedNeuromuscular Diseases | Amyotrophic Lateral Sclerosis (ALS)United States
-
University of FloridaU.S. Army Medical Research Acquisition ActivityRecruiting
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis-Relapsing-RemittingUnited States
-
Shirley Ryan AbilityLabCompletedSpinal Cord InjuriesUnited States
-
University of MiamiThe Craig H. Neilsen FoundationRecruitingSleep Apnea, Obstructive | Hypoxia | Spinal Cord InjuriesUnited States
-
Spaulding Rehabilitation HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingSpinal Cord InjuriesUnited States
-
Emory UniversityUniversity of Wisconsin, Madison; University of SaskatchewanCompletedSpinal Cord InjuryUnited States
-
Shirley Ryan AbilityLabUniversity of California, Los AngelesRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Shirley Ryan AbilityLabU.S. Department of EducationUnknownSpinal Cord InjuriesUnited States
-
University of Colorado, BoulderMedical University of South Carolina; University of Colorado, Denver; Eunice...Enrolling by invitationIncomplete Spinal Cord InjuryUnited States